Medical bottles and syringe are seen with Novo Nordisk brand displayed on a display within the background.
Nurphoto | Nurphoto | Getty Photos
Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected web revenue within the fourth quarter, amid hovering demand for its Wegovy weight problems medicine.
Web revenue for the fourth quarter got here in at 28.23 billion Danish kroner, versus the 26.09 billion Danish kroner anticipated.
The drug maker posted a 107% year-on-year enhance in Wegovy gross sales to 19.87 billion Danish kroner ($2.76 billion) within the three months to the tip of December, barely lacking the 20.02 billion Danish kroner forecast by analysts in a Factset ballot late Tuesday.
It is a breaking information story and might be up to date shortly.